VolitionRx (NYSE-A:VNRX) has announced its Nu.Q Vet Cancer Test is now available for pre-order to veterinarians at the point-of-care through Heska Corporation.
The Henderson, Nevada-based multi-national epigenetics company said Heska's Nu.Q Canine Cancer Screen and Monitor Test will operate on Heska's proprietary Element i+ Immunodiagnostic Analyzer, a point-of-care platform which provides veterinarians with rapid, accurate, low-cost, and easy-to-use on-site testing in the veterinary clinic, to support clinical decision-making and improve patient outcomes.
"This is a breakthrough moment for Volition; it is the first time the Nu.Q platform is available outside of centralised laboratory testing,” Volition Veterinary Diagnostics Development CEO Dr Tom Butera said in a statement.
READ: VolitionRx announces expansion of availability of Nu.Q Vet Cancer Test availability through IDEXX's reference laboratory network
“Our mission at Volition is to ensure that our Nucleosomics technology is accessible and affordable worldwide, to detect and monitor disease earlier and improve outcomes,” Butera added. “We are delighted to be working with Heska and their remarkable point-of-care technology to enable vets, pets, and pet families to benefit from our innovative technology. We are thrilled to advance towards full commercial launch and license payment milestones."
Heska CEO and president Kevin Wilson said the company’s transformative Nu.Q Canine Cancer Screen and Monitor Test is expected to revolutionize canine cancer patient management. Available now for pre-order, he said the screen and monitoring test will assist veterinarians to detect cancer early, in the clinic, in minutes, and for under $50, to support clinical decision-making during annual check-ups, regular wellness exams, healthcare interventions, treatment cycles, and remission.
“While we also offer this technology at the central reference lab, we believe the benefits of point-of-care cancer screening and monitoring are significant and will provide outsized benefits to veterinarians, nursing and technical teams, pets, and pet families,” Wilson added.
"With this forthcoming launch, millions of pets will have access to critical cancer screening and monitoring in the clinic, to catch, treat and drive recovery from cancers earlier, for better healthcare outcomes and peace of mind. We believe that this innovation will be transformative to veterinarian healthcare as Heska begins to roll it out exclusively to the point-of-care, with our global commercial launch targeted for early in the second quarter of this year.”
VolitionRX also told investors that the Nu.Q test will be showcased this weekend in Las Vegas at the 2023 Western Veterinary Conference, one of the world's largest veterinary conferences.
VolitionRx is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals.
Contact the author at stephen.gunnion@proactiveinvestors.com